Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Acquired resistance to an epidermal growth factor receptor-tyrosine kinase inhibitor (EGFR-TKI) in an uncommon G719S EGFR mutation.

Investigational new drugs - 1 Dec 2018

Osoegawa Atsushi, Hashimoto Takafumi, Takumi Yohei, Abe Miyuki, Yamada Tomonori, Kobayashi Ryoji, Miyawaki Michiyo, Takeuchi Hideya, Okamoto Tatsuro, Sugio Kenji

Abstract excerpt

Background Acquired resistance (AR) to an epidermal growth factor receptor-tyrosine kinase inhibitor (EGFR-TKI) is a common event, and several underlying mechanisms, including T790 M, MET amplification and PTEN downregulation, have been reported for the common EGFR mutations. EGFR G719X is an uncommon mutation that has been reported to show sensitivity to EGFR-TKIs. However, no established cell lines harboring...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Aged
Share to Base Sequence

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Cell Line, Tumor

Share to Drug Resistance, Neoplasm

Share to ErbB Receptors

Share to TSC1 gene

Share to Mutation

Share to Protein Kinase Inhibitors

Source

Identifiers

PMID: 29594878
DOI: 10.1007/s10637-018-0592-y

Genes

EGFR
PTEN
MET
TSC1

Variants

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Acquired resistance to an epidermal growth factor receptor-tyrosine kinase inhibitor (EGFR-TKI) in an uncommon G719S EGFR mutation.PMID 29594878Read ↗

Potential treatment strategy for the rare osimertinib resistant mutation EGFR L718QSemantic proximity Read ↗

Determining EGFR-TKI sensitivity of G719X and other uncommon EGFR mutations in non-small cell lung cancer: Perplexity and solution (Review).Semantic proximity Read ↗

T790M and acquired resistance of EGFR TKI: a literature review of clinical reports.Semantic proximity Read ↗

Rare EGFR exon 20 S768I mutation predicts resistance to targeted therapy: a report of two cases.Semantic proximity Read ↗

Epidermal growth factor receptor-activating mutation(E746_T751>VP) in pancreatic ductal adenocarcinoma responds to erlotinib, followed by epidermal growth factor receptor resistance-mediating mutation (A647T): A case report and literature review.Semantic proximity Read ↗

Mechanism of EGER-related cancer drug resistance.Semantic proximity Read ↗

Loss of an EGFR-amplified chromosome 7 as a novel mechanism of acquired resistance to EGFR-TKIs in EGFR-mutated NSCLC cells.Semantic proximity Read ↗

Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor Treatment Response in Advanced Lung Adenocarcinomas with G719X/L861Q/S768I Mutations.Semantic proximity Read ↗

Acquired Intergenic ANK3-RET Fusion as a Pralsetinib-Responsive Mechanism of Resistance to Osimertinib in EGFR-Mutated NSCLCSemantic proximity Read ↗

Conversion from the "oncogene addiction" to "drug addiction" by intensive inhibition of the EGFR and MET in lung cancer with activating EGFR mutation.Semantic proximity Read ↗

Mutational spectrum of acquired resistance to reversible versus irreversible EGFR tyrosine kinase inhibitors.Semantic proximity Read ↗

First Reported Case of Unexpected Response to an Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor in the I744M Uncommon EGFR Mutation.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.